Complement Activation

"Complement Activation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES.

Descriptor ID	D003167
MeSH Number(s)	G12.274
Concept/Terms	Complement Activation Complement Activation Activation, Complement Activations, Complement Complement Activations

Below are MeSH descriptors whose meaning is more general than "Complement Activation".

Biological Sciences [G]
Immune System Phenomena [G12]
Complement Activation [G12.274]

Below are MeSH descriptors whose meaning is more specific than "Complement Activation".

Complement Activation
Complement Pathway, Alternative
Complement Pathway, Classical
Complement Pathway, Mannose-Binding Lectin

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Complement Activation" by people in this website by year, and whether "Complement Activation" was a major or minor topic of these publications.

Bar chart showing 72 publications over 23 distinct years, with a maximum of 7 publications in 2010 and 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1998	1	0	1
1999	1	0	1
2001	0	2	2
2002	0	2	2
2003	1	0	1
2004	0	2	2
2005	1	1	2
2006	2	2	4
2007	1	2	3
2008	0	1	1
2009	0	2	2
2010	4	3	7
2011	2	3	5
2012	2	1	3
2013	0	1	1
2014	3	2	5
2015	2	1	3
2016	1	5	6
2017	2	2	4
2018	1	4	5
2019	1	1	2
2020	2	1	3
2021	6	1	7

Below are the most recent publications written about "Complement Activation" by people in Profiles.

Zheng C, Ricci J, Zhang Q, Alawieh A, Yang X, Nadig S, He S, Engel P, Jin J, Atkinson C, Tomlinson S. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation. Front Immunol. 2021; 12:785229.

View in: PubMed
Rohrer B, Parsons N, Annamalai B, Nicholson C, Obert E, Jones BW, Dick AD. Peptide-based immunotherapy against oxidized elastin ameliorates pathology in mouse model of smoke-induced ocular injury. Exp Eye Res. 2021 11; 212:108755.

View in: PubMed
Toutonji A, Mandava M, Guglietta S, Tomlinson S. Chronic complement dysregulation drives neuroinflammation after traumatic brain injury: a transcriptomic study. Acta Neuropathol Commun. 2021 07 19; 9(1):126.

View in: PubMed
Zheng C, Sleiman MM, Yang X, He S, Atkinson C, Tomlinson S. Increasing the efficacy and safety of a human complement inhibitor for treating post-transplant cardiac ischemia reperfusion injury by targeting to a graft-specific neoepitope. J Heart Lung Transplant. 2021 10; 40(10):1112-1121.

View in: PubMed
Mallah K, Couch C, Alshareef M, Borucki D, Yang X, Alawieh A, Tomlinson S. Complement mediates neuroinflammation and cognitive decline at extended chronic time points after traumatic brain injury. Acta Neuropathol Commun. 2021 04 20; 9(1):72.

View in: PubMed
Annamalai B, Parsons N, Nicholson C, Obert E, Jones B, Rohrer B. Subretinal Rather Than Intravitreal Adeno-Associated Virus-Mediated Delivery of a Complement Alternative Pathway Inhibitor Is Effective in a Mouse Model of RPE Damage. Invest Ophthalmol Vis Sci. 2021 04 01; 62(4):11.

View in: PubMed
Alawieh A, Chalhoub RM, Mallah K, Langley EF, York M, Broome H, Couch C, Adkins D, Tomlinson S. Complement Drives Synaptic Degeneration and Progressive Cognitive Decline in the Chronic Phase after Traumatic Brain Injury. J Neurosci. 2021 02 24; 41(8):1830-1843.

View in: PubMed
Banda NK, Tomlinson S, Scheinman RI, Ho N, Ramirez JR, Mehta G, Wang G, Vu VP, Simberg D, Kulik L, Holers VM. C2 IgM Natural Antibody Enhances Inflammation and Its Use in the Recombinant Single Chain Antibody-Fused Complement Inhibitor C2-Crry to Target Therapeutics to Joints Attenuates Arthritis in Mice. Front Immunol. 2020; 11:575154.

View in: PubMed
Larrauri B, Hester CG, Jiang H, Miletic VD, Malbran A, Bork K, Kaplan A, Frank M. sgp120 and the contact system in hereditary angioedema: A diagnostic tool in HAE with normal C1 inhibitor. Mol Immunol. 2020 03; 119:27-34.

View in: PubMed
Nguyen H, Alawieh A, Bastian D, Kuril S, Dai M, Daenthanasanmak A, Zhang M, Iamsawat S, Schutt SD, Wu Y, Sleiman MM, Shetty A, Atkinson C, Sun S, Varela JC, Tomlinson S, Yu XZ. Targeting the Complement Alternative Pathway Permits Graft Versus Leukemia Activity while Preventing Graft Versus Host Disease. Clin Cancer Res. 2020 07 01; 26(13):3481-3490.

View in: PubMed

People

Explore

Similar Concepts

Top Journals